# Viridian Therapeutics Inc. (VRDN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $22.92, market value $2.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Viridian Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 36.5×**. Each dollar of revenue is priced at 36.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.7×**. The shares trade at 4.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -12.9%** (5-yr avg -17.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -569.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -483.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -47.4%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -43.1%**. Return on all capital, debt included, is -43.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -43.0%**. Each dollar of assets produces -43.0% of profit.

## Financial health
- **Debt to equity: 0.03**. Debt is 0.03 times equity: a conservative balance sheet.
- **Current ratio: 12.65** (quick 12.65). Current assets cover the next year's liabilities 12.65 times.
- **Altman Z-score: 9.76**. A Z-score of 9.76 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Viridian Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 23.0%** (YTD -26.3%, 3-mo 45.2%). The shares are up 23.0% over twelve months including dividends.
- **From 52-week high: -33.2%** (73.9% above the low). Trading 33% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 1.13** (volatility 71%). Beta of 1.13 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VRDN · Page: https://foliofundamentals.com/stocks/vrdn

Not investment advice.